

CLAIM AMENDMENTS

1-34 (canceled)

35. 3,11b-*cis*-dihydrotetrabenazine.

36. A composition consisting of 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in substantially pure form.

37. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 which is in a (+)-isomeric form.


38. A composition comprising 3,11b-*cis*-dihydrotetrabenazine according to claim 35, the composition being substantially free of 3,11b-*trans*-dihydrotetrabenazine.

39. A composition comprising 3,11b-*cis*-dihydrotetrabenazine according to claim 35 and containing less than 5% of 3,11b-*trans*-dihydrotetrabenazine.


40. A composition according to claim 39 wherein the 3,11b-*cis*-dihydrotetrabenazine is a (+)-isomer.

41. A composition according to claim 40 wherein the 3,11b-*cis*-dihydrotetrabenazine is a (+)-isomer.


42. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a 2*S*,3*S*,11*bR* isomer having the formula (Ia):




43. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a 2*R*,3*R*,11b*S* isomer having the formula (Ib):



44. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a 2*R*,3*S*,11b*R* isomer having the formula (Ic):



45. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a 2*S*,3*R*,11b*S* isomer having the formula (Id):



46. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of a free base.

47. 3,11b-*cis*-dihydrotetrabenazine according to claim 35 in the form of an acid addition salt.

48. An acid addition salt of 3,11b-*cis*-dihydrotetrabenazine according to claim 47 wherein the salt is a methane sulphonate salt.


49. A pharmaceutical composition comprising 3,11b-*cis*-dihydrotetrabenazine according to claim 35 and a pharmaceutically acceptable carrier.

50. A pharmaceutical composition according to claim 49 wherein the 3,11b-*cis*-dihydrotetrabenazine is a (+)-isomer.

51. A method for the prophylaxis or treatment of a hyperkinetic movement disorder, which method comprises the administration of an effective prophylactic or therapeutic amount of 3,11b-*cis*-dihydrotetrabenazine according to claim 35.


52. A method according to claim 51 wherein the hyperkinetic movement disorder is selected from Huntington's disease, hemiballismus, senile chorea, tic, tardive dyskinesia and Tourette's syndrome.

53. A process for preparing 3,11b-*cis*-dihydrotetrabenazine according to claim 35, which process comprises the reaction of a compound of the formula (II):




with a reagent or reagents suitable for hydrating the 2,3-double bond in the compound of formula (II) and thereafter where required separating and isolating a desired 3,11b-*cis*-dihydrotetraabenazine isomer form.

54. A process for preparing 3,11b-*cis*-dihydrotetabenazine according to claim 35, which process comprises subjecting a compound of the formula (III):




to conditions for ring-opening the 2,3-epoxide group in the compound of the formula (III), and thereafter where required separating and isolating a desired 3,11b-*cis*-dihydrotetabenazine isomer form.

55. A compound of the formula (II):



56. A compound of the formula (III):



57. A Mosher's acid ester of 3,11b-*cis*-dihydrotetraabenazine.